Effectiveness and safety of encorafenib-cetuximab in BRAFV600E metastatic colorectal cancer: Confidence study.

被引：0

作者：

Fernandez Montes, Ana

Ros, Javier

Grana, Begona

Garcia-Alfonso, Pilar

Brozos, Elena

Melian, Marcos

Jimenez-Gordo, Ana M.

Martinez de Castro, Eva

Busquier, Isabel

Gallego, Javier

Gravalos, Cristina

Covela, Marta

Ruiz-Casado, Ana

Gonzalez Flores, Encarnacion

Safont, Mariajose

Maria Cano, Juana

Alonso Lopez, Carmen

Gomez-Reina, Maria Jose

Donnay, Olga

Aranda, Enrique

机构：

[1] Complexo Hosp Univ Ourense CHUO, Dept Med Oncol, Orense, Spain

[2] Vall dHebron Univ Hosp CHUO, Dept Med Oncol, Barcelona, Spain

[3] Vall dHebron Inst Oncol VHIO, Barcelona, Spain

[4] A Coruna Univ Hosp, Inst Invest Biomed INIBIC, La Coruna, Spain

[5] Hosp Univ Gregorio Maranon, Dept Med Oncol, Madrid, Spain

[6] CHUS, Santiago De Compostela, Spain

[7] Inst Valenciano Oncol, Valencia, Spain

[8] Hosp Univ Infanta Sofia, Dept Med Oncol, San Sebastian Los Reyes, Spain

[9] Univ Hosp Marques de Valdecilla, Dept Med Oncol, IDIVAL, Santander, Spain

[10] Hosp Prov Castellon, Valencia, Spain

[11] Hosp Gen Univ Elche, Alicante, Spain

[12] Hosp Univ 12 Octubre, Madrid, Spain

[13] Hosp Univ Lucas Augusti HULA, Lugo, Spain

[14] Hosp Univ Puerta de Hierro, Dept Med Oncol, Madrid, Spain

[15] Hosp Virgen de las Nieves, Granada, Spain

[16] Hosp Gen Valencia, Valencia, Spain

[17] Hosp Gen Univ Ciudad Real, Ciudad Real, Spain

[18] Complejo Hosp Univ Albacete, Albacete, Spain

[19] Hosp Univ Nuestra Senora de Valme, Seville, Spain

[20] Hosp Univ Princesa, Madrid, Spain

[21] Hosp Univ Reina Sofia, Cordoba, Spain

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

126

引用

页码：126 / 126

页数：1

共 50 条

[11] Encorafenib, cetuximab, and cytotoxic chemotherapy combinations in BRAFV600E CRC murine models
Woods, Melanie Nicole
De Falco, Vincenzo
Prisco, Claudia
Martini, Giulia
Guerrera, Luigi Pio
Belli, Valentina
Troiani, Teresa
Morris, Van K.
Shen, John Paul Y. C.
Lee, Hey Min
Villarreal, Oscar
Sorokin, Alexey
Marie, Preeti Kanikarla
Ciardiello, Fortunato
Kopetz, Scott
Napolitano, Stefania
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[12] Mutational profiles associated with resistance in patients with BRAFV600E mutant colorectal cancer treated with cetuximab and encorafenib plus /- binimetinib or alpelisib
Huijberts, Sanne C. F. A.
Boelens, Mirjam C.
Bernards, Rene
Opdam, Frans L.
BRITISH JOURNAL OF CANCER, 2021, 124 (01) : 176 - 182
[13] THE COST OF METASTATIC COLORECTAL CANCER PATIENTS WITH BRAFV600E MUTATIONS IN GREECE
Souglakos, I
Athanasiadis, I
Boukovinas, I
Karamouzis, M.
Koutras, A.
Papakotoulas, P.
Latsou, D.
Hatzikou, M.
Stamuli, E.
VALUE IN HEALTH, 2022, 25 (01) : S53 - S53
[14] The Evolutionary Landscape of Treatment for BRAFV600E Mutant Metastatic Colorectal Cancer
Mauri, Gianluca
Bonazzina, Erica
Amatu, Alessio
Tosi, Federica
Bencardino, Katia
Gori, Viviana
Massihnia, Daniela
Cipani, Tiziana
Spina, Francesco
Ghezzi, Silvia
Siena, Salvatore
Sartore-Bianchi, Andrea
CANCERS, 2021, 13 (01) : 1 - 15
[15] Unveiling BRAFV600E metastatic colorectal cancer as an entity of its own
Tabernero, J.
Elez, E.
Ros, J.
ANNALS OF ONCOLOGY, 2024, 35 : S1300 - S1300
[16] Metastatic pattern is a prognostic factor in BRAFV600E mutant colorectal cancer
Ji, Jingran
Sandhu, Jaideep
Wang, Chongkai
Fakih, Marwan
CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2023, 35
[17] Overcoming acquired MET amplification after encorafenib-cetuximab in BRAF-V600E mutated colorectal cancer
Ros, Javier
Elez, Elena
EUROPEAN JOURNAL OF CANCER, 2022, 172 : 326 - 328
[18] Encorafenib and cetuximab versus irinotecan/cetuximab or FOLFIRI/cetuximab in Chinese patients with BRAF V600E mutant metastatic colorectal cancer: The NAUTICAL CRC study.
Wang, Xicheng
Deng, Yanhong
Zhang, Yanqiao
Liu, Tianshu
Yuan, Xianglin
Yang, Jianwei
Zhang, Tao
Zang, Ai-min
Liu, Yu
Huang, Li
Ye, Feng
Zong, Hong
Ba, Yi
Klauck, Isabelle
Vedovato, Jean-Claude
Groc, Melanie
Guo, Angela
Shen, Lin
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA3559 - LBA3559
[19] Encorafenib plus cetuximab with or without binimetinib for BRAFV600E metastatic colorectal cancer (mCRC): Relationship between carcinoembryonic antigen (CEA) and clinical outcomes from BEACON CRC
Grothey, A.
Kopetz, S.
Yaeger, R.
Van Cutsem, E.
Wasan, H.
Desai, J.
Ciardiello, F.
Yoshino, T.
Maharry, K.
Christy-Bittel, J.
Gollerkeri, A.
Tabernero, J.
ANNALS OF ONCOLOGY, 2020, 31 : S243 - S243
[20] Safety of encorafenib, binimetinib, plus cetuximab for Japanese patients with BRAF V600E metastatic colorectal cancer
Yamaguchi, Toshifumi
Daisuke, Kotani
Atsuo, Takashima
Takeshi, Kato
Toshiki, Masuishi
Yoshito, Komatsu
Manabu, Shiozawa
Taito, Esaki
Naoki, Izawa
Shinji, Takeuchi
Hideaki, Bando
Satoru, Iwasa
Hiroko, Hasegawa
Taroh, Satoh
Hiroya, Taniguchi
Takayuki, Yoshino
ANNALS OF ONCOLOGY, 2022, 33 : S479 - S479

← 1 2 3 4 5 →